adverse events

Association between severe irAEs and PDCD1 polymorphism in mRCC 2:29
Association between severe irAEs and PDCD1 polymorphism in mRCC
Kazuyuki Numakura • 29 Jun 2021
Real-world analysis of AEs associated with alpha blockers and drugs for mRCC 2:38
Real-world analysis of AEs associated with alpha blockers and drugs for mRCC
Cosimo De Nunzio • 1 Jul 2021
Preliminary safety results of the MITOBCG study in NMIBC 1:37
Preliminary safety results of the MITOBCG study in NMIBC
Cosimo De Nunzio • 1 Jul 2021
SWOG S1216: ADT and TAK700 in prostate cancer 3:41
SWOG S1216: ADT and TAK700 in prostate cancer
Shilpa Gupta • 9 Jun 2021
VISION: Lu-177-PSMA-617 in mCRPC 4:48
VISION: Lu-177-PSMA-617 in mCRPC
Karim Fizazi • 7 Jun 2021
Treatment de-escalation in head and neck cancer 1:37
Treatment de-escalation in head and neck cancer
Ari Rosenberg • 8 Jun 2021
Final results from ClarIDHy: ivosidenib in IDH1-mutated CCA 2:42
Final results from ClarIDHy: ivosidenib in IDH1-mutated CCA
Ghassan Abou-Alfa • 2 Jun 2021
FIGHT-202: pemigatinib in CCA 1:42
FIGHT-202: pemigatinib in CCA
Ghassan Abou-Alfa • 2 Jun 2021
VISION: 177Lu-PSMA-617 in PSMA-positive mCRPC 3:56
VISION: 177Lu-PSMA-617 in PSMA-positive mCRPC
Scott Tagawa • 28 May 2021
Update from a phase 1 study of AMG 757 in SCLC 2:47
Update from a phase 1 study of AMG 757 in SCLC
Sanjay Popat • 31 Mar 2021
TheraP: LuPSMA versus cabazitaxel for prostate cancer 2:56
TheraP: LuPSMA versus cabazitaxel for prostate cancer
Michael Hofman • 16 Feb 2021
Incidence of pneumonitis in patients undergoing immunotherapy 1:48
Incidence of pneumonitis in patients undergoing immunotherapy
Alastair Greystoke • 30 Jan 2020
Can spinners improve understanding of adverse events in patients with cancer? 2:19
Can spinners improve understanding of adverse events in patients with cancer?
Lisa Holle • 10 Oct 2019
irAEs with single-agent PD-1 vs PD-L1 inhibitors 2:33
irAEs with single-agent PD-1 vs PD-L1 inhibitors
Petros Grivas • 30 Sep 2019
Evaluation of costs associated with AEs in urothelial cancer patients 4:14
Evaluation of costs associated with AEs in urothelial cancer patients
Petros Grivas
AdRad safety results: radium-223/VMAT RT in the first-line for metastatic prostate cancer 1:30
AdRad safety results: radium-223/VMAT RT in the first-line for metastatic prostate cancer
Joe O'Sullivan
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals